In women, breast cancer is the most common cancer, and the second leading cause of cancer-related death. When it metastasizes, it does so primarily to the lung, brain, and bone. Only limited treatment options are available, and scientists are working to identify and test new drug targets for the development of effective therapies.
Recent studies suggest that abnormal gene expression contributes significantly to tumor formation and progression. But the regulators of such changes in metastasis are poorly understood.
The Yale researchers analyzed gene expression datasets of human breast tumors, as well as those of cancer cells, and found that overexpression of the enzyme RBP2 is critical for breast cancer metastasis to the lung. Loss of RBP2, they also found, suppressed tumor formation in mouse models.
The authors say their evidence suggests that RBP2 regulates a critical epigenetic switch that sets the stage for tumor metastasis. They say the enzyme offers a novel target for development of therapies designed to inhibit tumor progression and metastasis.
“Metastasis is the major cause of breast cancer-related death,” said senior author Qin Yan, assistant professor of pathology at Yale School of Medicine. “Our study provides the first evidence, in genetically engineered mice, that a new class of enzymes could be targeted to suppress tumor metastasis.”
Other authors are Jian Cao, Zongzhi Liu, William Cheung, Minghui Zhao, Sophia Chen, Carmen Booth, and Don Nguyen of Yale; and Siew Wee Chan of the Institute of Molecular and Cell Biology in Singapore.
This study was supported by the grants from the Alexander and Margaret Stewart Trust, the Connecticut Department of Public Health, the American Cancer Society, and the National Institutes of Health (R01CA166376 and P30CA16359).
Contact Bill Hathaway [email protected] 203-432-1322